Immunai and the Parker Institute Collaborate to Build One of the Largest Single-Cell Datasets in Cancer

Immunai, a leading AI biotech company specializing in mapping the human immune system, and the Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, announced today that they will build the world’s largest single-cell dataset derived from a single cohort of patients treated with standard-of-care immunotherapy.

Under the collaboration with PICI, Immunai will perform single-cell RNA sequencing (scRNA-seq) and multi-omic profiling of patient blood samples collected from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) cohort, a prospective longitudinal study of 1,070 patients receiving immune checkpoint inhibitor treatment regimens in a community setting.

Data generated from RADIOHEAD will be integrated into Immunai’s AMICA™ (Annotated Multi-omic Immune Cell Atlas) to support comparative analysis across diverse cancer types. The RADIOHEAD cohort is pan-cancer, including samples from patients with non-small cell lung cancer, small cell lung cancer, gastric cancer, hepatocellular carcinoma, melanoma, and others.

To support this effort, Immunai will leverage 10x Genomics’ Chromium GEM-X single-cell technology to accelerate this large-scale data generation. The combined dataset will help researchers in identifying biological patterns of immune response and resistance, enabling the study of clinically relevant mechanisms that may help guide future therapeutic strategies.

“PICI was built to support bold science that brings real benefit to patients,” said Tarak Mody, PhD, Chief Business Officer at PICI. “Our mission to turn all cancers into curable diseases starts with understanding why treatments work for some people and not for others.” Our collaboration with Immunai gives researchers a powerful resource to decode immune responses in real-world patients—and ultimately, to bring better immunotherapies to the people who need them most.”

“What’s truly exciting about this collaboration is that the RADIOHEAD cohort allows us to publicly showcase the kind of single-cell multi-omic profiling we typically sequence privately with biopharma and biotechnology companies,” said Noam Solomon, PhD, CEO and Co-Founder of Immunai. “The type of advanced AI we apply to such datasets provides a unique glimpse into the depth of insights our platform can offer—and generates a rich dataset that gives scientists and drug developers the power to spot the patient groups most likely to benefit from new treatments—and perhaps more importantly, where they might not.”

About Immunai
Immunai is developing an AI model of the immune system, the IDE™ engine, leveraging its large proprietary clinically annotated single-cell multi-omics immunology knowledgebase AMICA™ and advanced artificial intelligence and machine learning, in order to discover and improve the development of novel immune modulating therapeutics. With a team of over 170 experts, the company collaborates with leading pharmaceutical firms and academic institutions. Immunai is headquartered in New York City and has raised close to $270 million in funding to date. Find out more at immunai.com and follow us on LinkedIn and X.

About the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is a 501c3 nonprofit organization driving the next generation of cancer treatment by accelerating the development of breakthrough immune therapies to turn all cancers into curable diseases. Founded in 2016 through the vision of Sean Parker, PICI unites the nation’s top cancer centers into a collaborative consortium that fuels high-risk, high-reward science with shared goals, data, and infrastructure. Unlike traditional research models, PICI goes beyond discovery by actively advancing promising innovations through clinical testing, company formation and incubation, and commercialization. PICI has supported more than 1,000 investigators across its network and has a portfolio that includes 17 biotech ventures with over $4B raised in capital. PICI is uniquely positioned to close the gap between scientific discovery and patient access. By integrating scientific excellence with entrepreneurial execution, PICI is reimagining how cures are made, and accelerating their path to the people who need them most. Find out more at parkerici.org and follow us on LinkedIn, X, Apple Podcasts and Spotify.

About RADIOHEAD
The RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program is a pan-tumor, prospective cohort study of 1,070 immunotherapy-naïve patients receiving standard-of-care immune checkpoint inhibitor regimens. Conducted across 49 U.S. community oncology clinics, the study includes over 3,700 longitudinal blood samples collected at pretreatment, early on-treatment, and immune-related adverse event timepoints, with a focus on major immuno-oncology indications such as non-small cell lung cancer (~1,400 samples) and malignant melanoma (~500 samples). Multi-omic profiling (including circulating tumor DNA analysis, whole-exome sequencing, transcriptomics, high-dimensional immune profiling, and serum proteomics) is paired with detailed clinical and demographic data to enable deep translational insights. This comprehensive dataset provides a unique opportunity to uncover mechanisms of response, resistance, and toxicity, and to apply machine learning approaches to explore immune and disease pathways.

About 10x Genomics
10x Genomics (NASDAQ: TXG) is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.

Contact Information

Jennifer Henry

PR for Immunai

VSC for Immunai

Contact via E-mail